JNJ-37822681 dihydrochloride

TargetMol
Product Code: TAR-T11722
Supplier: TargetMol
CodeSizePrice
TAR-T11722-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-5mg5mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-1mL1 mL * 10 mM (in DMSO)£184.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-10mg10mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-25mg25mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-50mg50mg£390.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11722-100mg100mg£547.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
JNJ-37822681 dihydrochloride is a novel, highly selective dopamine D? receptor antagonist characterized by a rapid dissociation rate from the dopamine D? receptor. JNJ-37822681 dihydrochloride shows a moderate binding affinity for the dopamine D2L receptor with a Ki of 158 nM.
CAS:
2108806-02-4
Formula:
C17H19Cl2F5N4
Molecular Weight:
445.26
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.98
SMILES:
Cl.Cl.Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F
Target:
Dopamine Receptor

References

1. Langlois X, et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther. 2012 Jul;342(1):91-105. 2. de Waal EJ,et al. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics. J Appl Toxicol. 2014 Sep;34(9):974-92. 3. Daly EJ, et al. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia. Ann Clin Psychiatry. 2013 Aug;25(3):173-83. 4. Hoeben E, et al. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D?-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D?-receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.